ALK and non-small cell lung carcinoma: Based on our results, we suggest that the next step in the development of an effective ALK treatment might be to evaluate the relationship between body size variables (evaluated with impedancemetry tests) and efficacy in the course of ALK inhibitors in NSCLC patients, also considering the influence of weight gain as a common side effect of ALK TKIs.